New cancer drug enters first human trials for Tough-to-Treat tumors
NCT ID NCT06383871
Summary
This is the first study in people to test a new oral drug called HRS-7058. It aims to find a safe dose and see early signs of effectiveness in adults with advanced solid tumors that have a specific genetic change (KRAS G12C mutation). The study will enroll about 233 participants to monitor side effects and how the drug behaves in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMOUR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
Contact
Conditions
Explore the condition pages connected to this study.